The Cytel blog keeps you up to speed with the latest developments in biostatistics and clinical biometrics.

Career Perspectives: Interview with Meredith Alm, Manager, QA Compliance

August 23, 2018

Cytel has grown significantly over the last 30 years, with operations across North America, Europe, and India. All of our processes, talent, and expertise are applied to maximizing the value of clinical data. At Cytel, quality comes first, and our QA team are committed to ensuring processes are in place to support our services.

In this blog we talk to Meredith who lives in Somerville, Massachusetts, to find out more about her career path, current role at Cytel, and her interests outside of work.

Read More

How to ensure independence of QC in statistical programming 

November 11, 2016

A solid and robust QC process is one vital component of ensuring quality programming delivery. Angelo Tinazzi and Cedric Marchand presented at the PhUSE conference recently on the topic of ‘What Auditors want’. As part of this well received presentation, the duo discussed the question of independence of QC and how to make sure this is fully observed.

In this blog we’ll walk through their recommendations to ensure independence of QC in programming.

Read More

Regulation and Reproducibility: Can You Reproduce Your Clinical Trial Results?

May 15, 2015

Cytel Clinical Research Services

Imagine that it’s been three years since the completion of a trial, and that suddenly a regulatory body calls into question the findings:

  • Was a particular trial site operating properly?
  • Can you clarify an aspect of the results? 
  • Why did you make a particular decision at an interim look?

Suddenly, your somewhat old data needs to be able to reproduce your initial findings. In such a case, how long would it take you to satisfy the regulatory body?

Read More

Impact of Study Design and Development Strategy on Pharmaceutical Programs and Portfolios

September 2, 2014

As more clinical trials make use of adaptive designs, investors have come to realize that high quality trial designs can result in significant improvements to a trial’s financial risk profile. Regardless of a trial’s eventual success or failure, a well-constructed design provides a drug with the highest possible probability of success while mitigating financial risk.

Read More

Statisticians on Software Development Part I: Statisticians from Cytel, SAS and Stata talk Software Development

August 26, 2014

During an invited speakers session at the lnternational Society for Clinical Biostatistics, Cytel VP Yannis Jemiai was joined by R.N. Rodriguez from the SAS Institute and IR White (formerly of Stata), to discuss innovations in software for clinical trials.

Read More

What Horsepower Can Teach us about Well-Powered Trials

August 12, 2014

Beyond Wild Horses: Developing Innovation at Cytel

"Horse-and-pony" by arjecahn on flickr. - http://www.flickr.com/photos/arje/95322238/.
********************
Automotive affluential, Henry Ford, once said: "If I'd asked customers what they wanted, they would have told me a faster horse!" 
 
Thanks to a keen understanding of customers' needs and not merely a statement of their wants, Henry Ford was able to revolutionize the automotive industry with the first 26-horsepower engine for the Cadillac Automobile Company (then known as the Henry Ford Company). Not long afterwards, Ford designed the engine for the Ford Model 999 racer, with a reported horsepower of over 86. He went on to develop the Ford Model T and Model A, and the Ford Trimotor aircraft. 
Read More

'Multivariate Approaches for Risk-Based Monitoring' An Adaptive Design (Slides Attached)

July 1, 2014

A recent Cytel Seminar on Adaptive Statistical Designs featured a talk by Michael Elashoff (Patient Profiles) on Multivariate Approaches for Risk-Based Monitoring. Elashoff, a former statistical reviewer at the Food and Drug Administration, recommended combining cluster and rules based methods for statistical monitoring. Such adaptive monitoring approaches can substantially reduce the time and expense of data monitoring while ensuring consistently high data quality. 

Read More

Data Management & Biostatistics I: Improving Trial Quality

May 22, 2014

This is the first of a three part post in which we will consider (i) improvements to trial quality that result from bundling data management with biostatistics, (ii) reductions in cost and study length that result from bundling data management with biostatistics, and (iii) the contributions of statistical innovation to clinical data management, such as those by Cytel Board member Professor Marvin Zelen (Research Professor and former Chair of Biostatistics at the Harvard School of Public Health.)

Read More